These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 18376220)

  • 21. Phase II study of capecitabine and oxaliplatin for advanced adenocarcinoma of the small bowel and ampulla of Vater.
    Overman MJ; Varadhachary GR; Kopetz S; Adinin R; Lin E; Morris JS; Eng C; Abbruzzese JL; Wolff RA
    J Clin Oncol; 2009 Jun; 27(16):2598-603. PubMed ID: 19164203
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tesetaxel, a new oral taxane, in combination with capecitabine: a phase I, dose-escalation study in patients with advanced solid tumors.
    Saif MW; Sarantopoulos J; Patnaik A; Tolcher AW; Takimoto C; Beeram M
    Cancer Chemother Pharmacol; 2011 Dec; 68(6):1565-73. PubMed ID: 21547572
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A dose escalation study of the biweekly administration of paclitaxel, oxaliplatin and capecitabine in patients with advanced solid tumors.
    Saridaki Z; Bozionelou V; Kentepozidis N; Kotsakis A; Vardakis N; Kalykaki A; Gioulbasanis I; Karampeazis A; Vamvakas L; Georgoulias V; Mavroudis D
    Oncology; 2007; 72(1-2):45-50. PubMed ID: 17998790
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Multicentre phase I-II trial of capecitabine and oxaliplatin in combination with radiotherapy for unresectable pancreatic and biliary tract cancer: The CORGI-U study.
    Gunnlaugsson A; Anderson H; Lind P; Glimelius B; Johnsson A
    Radiother Oncol; 2010 Jun; 95(3):292-7. PubMed ID: 20451275
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Capecitabine plus weekly oxaliplatin in gastrointestinal tumors: a phase I study.
    Carlomagno C; Orditura M; Pepe S; De Vita F; Romano C; Ciardiello F; Ferrara C; Martinelli E; Bianco R; Aurilio G; D'Agostino D; Tortora G; Catalano G; De Placido S
    Am J Clin Oncol; 2006 Feb; 29(1):85-9. PubMed ID: 16462509
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A Phase I study of 9-nitrocamptothecin given concurrently with capecitabine in patients with refractory, metastatic solid tumors.
    Michaelson MD; Ryan DP; Fuchs CS; Supko JG; Garcia-Carbonero R; Paul Eder J; Clark JW
    Cancer; 2003 Jan; 97(1):148-54. PubMed ID: 12491516
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase I trial of bortezomib in combination with docetaxel in patients with advanced solid tumors.
    Messersmith WA; Baker SD; Lassiter L; Sullivan RA; Dinh K; Almuete VI; Wright JJ; Donehower RC; Carducci MA; Armstrong DK
    Clin Cancer Res; 2006 Feb; 12(4):1270-5. PubMed ID: 16489083
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase I pharmacokinetic study of chronomodulated dose-intensified combination of capecitabine and oxaliplatin (XELOX) in metastatic colorectal cancer.
    Farid M; Chowbay B; Chen X; Tan SH; Ramasamy S; Koo WH; Toh HC; Choo SP; Ong SY
    Cancer Chemother Pharmacol; 2012 Jul; 70(1):141-50. PubMed ID: 22648745
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase I study of docetaxel, oxaliplatin and capecitabine (TEX) as first line therapy to patients with advanced gastro-oesophageal cancer.
    Andersen M; Schønnemann KR; Yilmaz M; Jensen HA; Vestermark LW; Pfeiffer P
    Acta Oncol; 2010 Nov; 49(8):1246-52. PubMed ID: 20429725
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intermittent weekly high-dose capecitabine in combination with oxaliplatin: a phase I/II study in first-line treatment of patients with advanced colorectal cancer.
    Scheithauer W; Kornek GV; Raderer M; Schüll B; Schmid K; Längle F; Huber H
    Ann Oncol; 2002 Oct; 13(10):1583-9. PubMed ID: 12377646
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Capecitabine (Xeloda) in combination with oxaliplatin: a phase I, dose-escalation study in patients with advanced or metastatic solid tumors.
    Díaz-Rubio E; Evans TR; Tabemero J; Cassidy J; Sastre J; Eatock M; Bisset D; Regueiro P; Baselga J
    Ann Oncol; 2002 Apr; 13(4):558-65. PubMed ID: 12056706
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A phase II study of sorafenib, oxaliplatin, and 2 days of high-dose capecitabine in advanced pancreas cancer.
    Makielski RJ; Lubner SJ; Mulkerin DL; Traynor AM; Groteluschen D; Eickhoff J; LoConte NK
    Cancer Chemother Pharmacol; 2015 Aug; 76(2):317-23. PubMed ID: 26068189
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase I study of short-time oxaliplatin, capecitabine and epirubicin (EXE) as first line therapy in patients with non-resectable gastric cancer.
    Dupont J; Jensen HA; Jensen BV; Pfeiffer P
    Acta Oncol; 2007; 46(3):330-5. PubMed ID: 17450468
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A phase I study of capecitabine and a modulatory dose of irinotecan in metastatic breast cancer.
    O'connor T; Rustum Y; Levine E; Creaven P
    Cancer Chemother Pharmacol; 2008 Jan; 61(1):125-31. PubMed ID: 17426973
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase I trial using the proteasome inhibitor bortezomib and concurrent chemoradiotherapy for head-and-neck malignancies.
    Kubicek GJ; Axelrod RS; Machtay M; Ahn PH; Anne PR; Fogh S; Cognetti D; Myers TJ; Curran WJ; Dicker AP
    Int J Radiat Oncol Biol Phys; 2012 Jul; 83(4):1192-7. PubMed ID: 22245208
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A tailored regimen including capecitabine and oxaliplatin for treating elderly patients with metastatic colorectal carcinoma Southern Italy Cooperative Oncology Group trial 0108.
    Comella P; Gambardella A; Farris A; Maiorino L; Natale D; Massidda B; Casaretti R; Tafuto S; Lorusso V; Leo S;
    Crit Rev Oncol Hematol; 2005 Feb; 53(2):133-9. PubMed ID: 15661564
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase I trial of GTI-2040, oxaliplatin, and capecitabine in the treatment of advanced metastatic solid tumors: a California Cancer Consortium Study.
    Shibata SI; Doroshow JH; Frankel P; Synold TW; Yen Y; Gandara DR; Lenz HJ; Chow WA; Leong LA; Lim D; Margolin KA; Morgan RJ; Somlo G; Newman EM
    Cancer Chemother Pharmacol; 2009 Nov; 64(6):1149-55. PubMed ID: 19322566
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A phase I study of the oral platinum agent satraplatin in sequential combination with capecitabine in the treatment of patients with advanced solid malignancies.
    Gallerani E; Bauer J; Hess D; Boehm S; Droege C; Jeckelmann S; Miani M; Herrmann R; Marsoni S; Sperka S; Sessa C
    Acta Oncol; 2011 Oct; 50(7):1105-10. PubMed ID: 21184645
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A phase I safety, tolerability, and pharmacokinetic study of enzastaurin combined with capecitabine in patients with advanced solid tumors.
    Camidge DR; Gail Eckhardt S; Gore L; O'Bryant CL; Leong S; Basche M; Holden SN; Musib L; Baldwin J; Darstein C; Thornton D; Finn RS; Britten CD
    Anticancer Drugs; 2008 Jan; 19(1):77-84. PubMed ID: 18043132
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase I study of two schedules of oral S-1 in combination with fixed doses of oxaliplatin and bevacizumab in patients with advanced solid tumors.
    Chung KY; Saito K; Zergebel C; Hollywood E; Segal M; Saltz LB
    Oncology; 2011; 81(2):65-72. PubMed ID: 21968463
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.